A butcher at a market in Hangzhou, Jiangsu on March 29, 2026. Photo: VCG China’s wholesale pork prices have plummeted to nearly an eight-year low, prompting government authorities to escalate market interventions amid a severe supply glut and sluggish consumer demand. The national average wholesale price of pork fell 1% from the previous day to 15.3 yuan ($2.22) per kilogram on Tuesday, according ...
A butcher at a market in Hangzhou, Jiangsu on March 29, 2026. Photo: VCG China’s wholesale pork prices have plummeted to nearly an eight-year low, prompting government authorities to escalate market interventions amid a severe supply glut and sluggish consumer demand. The national average wholesale price of pork fell 1% from the previous day to 15.3 yuan ($2.22) per kilogram on Tuesday, according to the Ministry of Agriculture and Rural Affairs. Caixin data shows that since June 2013, average prices have only dipped below the 16-yuan mark once, in May 2018. In the week from March 20 to 26, prices dropped 23.4% from the same period last year.
NewcelX ( NCEL ) announced on Wednesday that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the company’s common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the company is selling an aggregate of 490,907 common shares (and common sha...
NewcelX ( NCEL ) announced on Wednesday that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the company’s common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at $3.025 per share. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026. The company intends to use the net proceeds from the offering, together with its previously announced $25M equity line, to advance NCEL-101, NewcelX’s lead program for Type 1 Diabetes, in collaboration with Eledon Pharmaceuticals, its other development pipeline programs, working capital, and general corporate purposes. NCEL +7.07% premarket to $2.27. Source: Press Release More on NLS Pharmaceutics Financial information for NLS Pharmaceutics
Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immunic ( IMUX ) on Wednesday said it has received written notice from Nasdaq, informing that it has regained compliance with the minimum bid price requirement as the closing bid price of the company's common stock was at $1.00 per share or greater for at least 20 consecutive business days, satisfying the Nasdaq requirement on March 26, 2026. IMUX +5.4% premarket to $1.17. Source: Press Release Mo...
Immunic ( IMUX ) on Wednesday said it has received written notice from Nasdaq, informing that it has regained compliance with the minimum bid price requirement as the closing bid price of the company's common stock was at $1.00 per share or greater for at least 20 consecutive business days, satisfying the Nasdaq requirement on March 26, 2026. IMUX +5.4% premarket to $1.17. Source: Press Release More on Immunic Immunic garners new Buy at Guggenheim on lead asset Immunic rises after $400M private placement, leadership transition Seeking Alpha’s Quant Rating on Immunic Historical earnings data for Immunic Financial information for Immunic
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
(RTTNews) - The U.K. stock market's benchmark index FTSE 100 moved up sharply on Wednesday thanks to fairly strong buying across the board amid growing optimism about a de-escalation in tensions in the Middle East. Stocks from banking, mining and travel sectors moved up sharply.
(RTTNews) - The U.K. stock market's benchmark index FTSE 100 moved up sharply on Wednesday thanks to fairly strong buying across the board amid growing optimism about a de-escalation in tensions in the Middle East. Stocks from banking, mining and travel sectors moved up sharply.
InTest Corporation ( INTT ) announced on Wednesday that Rich Rogoff , division president of InTest’s environmental technologies division, has also been named president and chief executive officer of InTest Corporation and appointed to the InTest board of directors, replacing Nick Grant, who has served as president, CEO, and board member since 2020, effective immediately. Rogoff joined InTest in Oc...
InTest Corporation ( INTT ) announced on Wednesday that Rich Rogoff , division president of InTest’s environmental technologies division, has also been named president and chief executive officer of InTest Corporation and appointed to the InTest board of directors, replacing Nick Grant, who has served as president, CEO, and board member since 2020, effective immediately. Rogoff joined InTest in October 2021 as vice president of corporate development. In that role he led InTest’s acquisitions of Acculogic, Videology and Alfamation and on an interim basis ran InTest’s process technologies and environmental technologies divisions before being promoted to division president of environmental technologies in June 2025. Earlier in his career, Rogoff spent seven years at Onto Innovation and one of its predecessor companies as vice president and business unit manager of Lithography Systems and then vice president of Strategic Initiatives and Integration Management Office. Before that, he spent more than 20 years at ASML. Source: Press Release More on inTest InTEST outlines $125M–$130M 2026 revenue target amid backlog growth and diversification strategy inTest Non-GAAP EPS of $0.16 beats by $0.05, revenue of $32.8M beats by $1.57M Seeking Alpha’s Quant Rating on inTest